Cabozantinib with or without Panitumumab for RAS wild-type metastatic colorectal cancer: impact of MET amplification on clinical outcomes and circulating biomarkers-论文-万方医学网

首页> > Cabozantinib with or without Panitumumab for RAS wild-type metastatic colorectal cancer: impact of MET amplification on clinical outcomes and circulating biomarkers

Cabozantinib with or without Panitumumab for RAS wild-type metastatic colorectal cancer: impact of MET amplification on clinical outcomes and circulating biomarkers

导出原文传递

翻译打印收藏纠错

第一作者： Jia, Jingquan

作者： Jia, Jingquan ^[1] ; Howard, Lauren ^[2] ; Liu, Yingmiao ^[3] ; Starr, Mark D. ; Brady, John C. ; Niedzwiecki, Donna ; Strickler, John H. ; Nixon, Andrew B.

作者单位： Med Ctr,Duke Univ ^[1] Duke Dept Biostat & Bioinformat ^[2] Duke Canc Inst ^[3]

关键词 Cabozantinib Panitumumab Prognostic biomarker Phase II clinical trial Metastatic colorectal cancer PROGNOSTIC MARKER OPEN-LABEL MUTATIONS RESISTANCE SIGNATURES CETUXIMAB KRAS

发布时间 2022-04-21

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交

浏览0

相似文献

中文期刊
外文期刊
学位论文
会议论文

参考文献：
指定格式：	NoteExpress EndNote RefWorks NoteFirst

法律状态公告日	法律状态	法律状态信息

检索历史清除

Cabozantinib with or without Panitumumab for RAS wild-type metastatic colorectal cancer: impact of MET amplification on clinical outcomes and circulating biomarkers

相似文献

同项目论文

相关期刊

检索历史 清除

Cabozantinib with or without Panitumumab for RAS wild-type metastatic colorectal cancer: impact of MET amplification on clinical outcomes and circulating biomarkers

相似文献

同项目论文

相关期刊

检索历史清除